Search - tctmd.com

Displaying 1 - 20 of 133

Sort: Relevancy | Date

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

Presenter: Grant Reed

February 28, 2016

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI

Presenter: Dominick J. Angiolillo

February 09, 2016

Presentation

Timing of Clopidogrel Loading in US Practice

Presenter: Gregg W. Stone

February 08, 2016

Presentation

Premature Clopidogrel Discontinuation After DES Placement in a Large Urban Safety-Net Hospital

Presenter: H. Khalili

December 09, 2015

Presentation

ADAPT-DES Subanalaysis: Proton Pump Inhibitors (PPIs), Platelet Reactivity, and Cardiovascular Outcomes After DES in Clopidogrel-Treated Patients

Presenter: Giora Weisz

October 28, 2015

Presentation TCT 2015

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Presenter: Steven R. Bailey, Patrick W. Serruys, Renato Valenti

October 15, 2015

Presentation TCT 2015

Russia Presents: A Case of Early Stent Thrombosis in a Clopidogrel Low-Responder Patient

Presenter: Graham A. Cassel, Nick Curzen, Niall T. Mulvihill, Sergey A. Abugov

October 12, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

Presenter: R. Valenti

September 17, 2015

Presentation

Concomitant PPI Use, Platelet Activity, and Clinical Outcomes in ACS Patients Treated With Prasugrel vs Clopidogrel and Managed Without Revascularization

Presenter: Jose Carlos Nicolau

June 17, 2015

Presentation

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

Presenter: Usman Baber

May 11, 2015

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Presenter: Roxana Mehran

May 08, 2015

Presentation

Prognostic Impact of Clopidogrel Pretreatment in Patients With ACS Managed Invasively

Presenter: Manuel Almendro-Delia

February 05, 2015

Presentation

Impact of Diabetes and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients with Stable CAD Receiving DES

Presenter: Laurent Feldman

October 06, 2014

Presentation

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Presenter: J.M. Cubero

October 06, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Presenter: Armando P?rez de Prado

September 16, 2014

Presentation TCT 2014

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Presenter: Jos? Mar?a Cubero G?mez

September 16, 2014

Advertisement

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

Ticagrelor vs Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI

Timing of Clopidogrel Loading in US Practice

Premature Clopidogrel Discontinuation After DES Placement in a Large Urban Safety-Net Hospital

ADAPT-DES Subanalaysis: Proton Pump Inhibitors (PPIs), Platelet Reactivity, and Cardiovascular Outcomes After DES in Clopidogrel-Treated Patients

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Russia Presents: A Case of Early Stent Thrombosis in a Clopidogrel Low-Responder Patient

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

Concomitant PPI Use, Platelet Activity, and Clinical Outcomes in ACS Patients Treated With Prasugrel vs Clopidogrel and Managed Without Revascularization

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Prognostic Impact of Clopidogrel Pretreatment in Patients With ACS Managed Invasively

Impact of Diabetes and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients with Stable CAD Receiving DES

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content